Treatment of ringworm (a fungal infection of skin) with combination of two oral antifungal drugs (terbinafine and griseofulvin)
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2019/06/019778
- Lead Sponsor
- Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Patients with clinical diagnosis of tinea corporis, tinea cruris or tinea faciei or a combination of these conditions
2. Microscopic confirmation of diagnosis
(a) pregnancy
(b) lactation
(c) tinea elsewhere, eg, onychomycosis
(d) another skin disease at the same site
(e) inability to come for follow up
(f) intake of terbinafine or griseofulvin in past 1 month
(g) history of allergy to terbinafine or griseofulvin
(h) present history of liver, renal or ischemic heart disease
(i) patients on treatment with drugs that have interaction with terbinafine or griseofulvin
(j) patient requiring antihistamines due to co-existing skin diseases as urticaria
(k) abnormal CBC (Hb <9, platelet count < 1 lakh), LFT, RFT, plasma glucose (fasting and postprandial), HbA1C, fasting lipid profile, urine routine and microscopy, ECG
(l) patients on treatment from skin OPD who is satisfied with the treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method